KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Assets (2016 - 2025)

Jazz Pharmaceuticals has reported Assets over the past 16 years, most recently at $11.7 billion for Q4 2025.

  • Quarterly results put Assets at $11.7 billion for Q4 2025, down 2.94% from a year ago — trailing twelve months through Dec 2025 was $11.7 billion (down 2.94% YoY), and the annual figure for FY2025 was $11.7 billion, down 2.94%.
  • Assets for Q4 2025 was $11.7 billion at Jazz Pharmaceuticals, up from $11.4 billion in the prior quarter.
  • Over the last five years, Assets for JAZZ hit a ceiling of $13.2 billion in Q2 2021 and a floor of $6.8 billion in Q1 2021.
  • Median Assets over the past 5 years was $11.4 billion (2024), compared with a mean of $11.3 billion.
  • Biggest five-year swings in Assets: soared 117.8% in 2021 and later decreased 16.78% in 2022.
  • Jazz Pharmaceuticals' Assets stood at $12.3 billion in 2021, then fell by 11.9% to $10.8 billion in 2022, then rose by 5.15% to $11.4 billion in 2023, then rose by 5.43% to $12.0 billion in 2024, then decreased by 2.94% to $11.7 billion in 2025.
  • The last three reported values for Assets were $11.7 billion (Q4 2025), $11.4 billion (Q3 2025), and $10.9 billion (Q2 2025) per Business Quant data.